ISRCTN72858898已完成不适用
A phase IV, single centre, open-label study to investigate the persistence of antibodies six years after priming immunisation with Meningococcal C conjugate vaccine and induction of long term immunological memory by assessing persistence of memory B cells and response to the Hib-MenC (Menitorix®) vaccine, in healthy children six to 12 years of age
niversity of Oxford (UK)0 个研究点目标入组 250 人开始时间: 2006年9月4日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 250
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Participant?s parent or legally authorised representative is willing and able to give written informed consent for participation after the nature of the study has been explained
- •2. Male or Female, aged six years (+ zero days) to 12 years (+ 364 days) on the day of enrolment
- •3. In good health as determined by:
- •3.1. medical history
- •3.2. pre-vaccination check performed by a physician if indicated by history
- •3.3. clinical judgment of the investigator
- •4. Able (in the investigators opinion) and willing to comply with all study requirements including being available for all the visits scheduled in the study
- •5. Parent or legally authorised representative is willing to allow his or her child?s (the participant?s) General Practitioner to be notified of participation in the study and contacted if required for confirmation of vaccination history
- •6. Whose parent or legally authorised representative believes to their best knowledge that their child has received all the recommended vaccinations as part of the UK routine childhood immunisation schedule (including Haemophilus influenzae B (Hib) if aged six months to four years in April 2003 (received 4/2003 - 12/2004) and Meningococcal C (MenC) if aged six months to 18 years in Nov 1999 (received 11/1999 - 06/2001) as part of the UK ?catch up? vaccination campaigns)
排除标准
- •1. Have a history of any anaphylactic shock, asthma, urticaria or other allergic reaction after previous vaccinations or known hypersensitivity to any vaccine component
- •2. Axillary temperature more than or equal to 38.0°C or presence of any systemic illness on the day of enrolment
- •3. Have experienced significant acute or chronic infection within the previous seven days or have experienced fever (more than or equal to 38.0°C) within the previous three days
- •4. Receipt of systemic antibiotics (either oral or parenteral) will delay enrolment until at least 14 days after cessation of antibiotics, with the exception of beta-lactam antibiotics (examples: penicillin, amoxicillin, ceftriaxone, cefuroxime, cephalexin, etc.) who may be enrolled seven days after the last dose
- •5. Have a previous clinical or bacteriological or suspected diagnosis of meningitis
- •6. Have a history of household contact or intimate exposure to an individual with culture proven Neisseria meningitis or Hib disease in the previous 60 days
- •7. Have a present or suspected serious disease such as metabolic, cardiac, autoimmune, endocrine (including insulin dependent diabetes), significant hepatic or renal impairment or progressive neurological impairment
- •8. Have any immunodeficiency, including use of systemic corticosteroids for more than five days or in a daily dose more than 1 mg/kg/day prednisone or equivalent for less than or equal to five days in the previous 30 days (inhaled high-potency corticosteroids equivalent to budesonide 800 mcg/day or fluticasone 750 mcg/day)
- •9. Have a genetic anomaly e.g. Down?s syndrome
- •10. Born after a gestation period of less than 36 weeks or more than 42 weeks
- •11. Have scheduled elective surgery or other procedures requiring general anaesthesia during the study
- •12. Have received of any blood, blood products or parenteral immunoglobulin preparation within the past 12 weeks
- •13. Have received any additional doses of Hib or MenC vaccines in addition to those given in accordance with the UK routine immunisation schedule or ?catch up? campaigns
- •14. Participants who have participated in another research study involving an investigational product in the past 12 weeks or are planning to receive a vaccine or investigational product within the next month
- •15. Have a known bleeding diathesis or any condition associated with a prolonged bleeding time
- •16. Any other significant disease or disorder which, in the opinion of the investigator, may either put the participant at risk because of participation in the study, or may influence the result of the study, or the participant?s ability to participate in the study
研究者
相似试验
进行中（未招募）
1 期
A Phase IV, Single Centre, Open-label Study to Investigate the Kinetics of the B Cell Response to the First and the Third Immunization with Chiron Meningococcal C Conjugate Vaccine Menjugate® Administered to Healthy Infants at 2, 3 and 4 Months of Age - N/AHealthy subjects without known medicial conditions will be vaccinated against Neisseria meningitidis serogroup C. Active prevention of meningococcal C disease caused by Neisseria meningitidis serogroup CEUCTR2004-004962-33-GBChiron S.r.l.75
进行中（未招募）
1 期
A Phase IV, Single Centre, Open-label Study to Investigate the Kinetics of the B Cell Response to the C saccharide component of Chiron’s Meningococcal C Conjugate Vaccine (Menjugate®) Administered to Healthy Children at least 12 Months of Age After Priming with Menjugate® at 2, 3 and 4 Months of Age.EUCTR2006-000732-28-GBChiron S.r.l.
进行中（未招募）
不适用
Evaluation of the long-term persistence of hepatitis A antibodies in healthy adults who were vaccinated 21-25 years earlier with GlaxoSmithKline (GSK) Biologicals’ hepatitis A vaccine, Havrix®.Healthy volunteers (Vaccination against hepatitis A in healthy adults)MedDRA version: 16.1Level: LLTClassification code 10052551Term: Hepatitis A virusSystem Organ Class: 100000004848EUCTR2013-001918-15-BEGlaxoSmithKline Biologicals
进行中（未招募）
1 期
A clinical study to investigate the infliximab serum concentration of Remsima™ (infliximab biosimilar) after switching from Remicade (infliximab) in subjects with Crohn’s Disease (CD), Ulcerative Colitis (UC) or Rheumatoid Arthritis (RA) in stable remission.Crohn’s Disease (CD), Ulcerative Colitis (UC) or Rheumatoid Arthritis (RA).EUCTR2014-004904-31-NLMundipharma Pharmaceuticals B.V.
进行中（未招募）
1 期
A clinical study to investigate the infliximab serum concentration of Remsima™ (infliximab biosimilar) after switching from Remicade (infliximab) in subjects with Crohn’s Disease (CD), Ulcerative Colitis (UC) or Rheumatoid Arthritis (RA) in stable remission.EUCTR2014-004904-31-BEMundipharma Pharmaceuticals B.V.156